Abstract:Receptor activator of nuclear factor-kappaB ligand (RANKL) is a key factor necessary for osteoclast differentiation and activation. Mutations within the TNF-like core domain of RANKL have been recently reported in patients with osteoclast-poor autosomal recessive osteopetrosis. However, the functional consequence owing to RANKL mutations has not been well characterized. Here we describe the functional propensity of RANKL mutants in osteoclast differentiation and their impact on RANKL-mediated signaling cascades. Recombinant RANKL (rRANKL) mutants within the TNF-like core domain exhibited diminished osteoclastogenic potential as compared with wild-type rRANKL1 encoding the full TNF-like core domain [amino acids (aa) 160-318]. Consistent with the insufficient activities on osteoclastogenesis, rRANKL mutants showed reduced activation of nuclear factor-kappaB, IkappaBalpha degradation, and ERK phosphorylation. In addition, we found that rRANKL mutants interfered with wild-type rRANKL-induced osteoclastogenesis with deletion mutant rRANKL5 (aa 246-318) exhibiting the greatest inhibitory effect. The same mutant also significantly reduced wild-type rRANKL1 (aa 160-318)-induced osteoclastic bone resorption in vitro. BIAcore assays demonstrated that rRANKL5 alone, lacking the AA'' and CD loops, weakly binds to receptor activator of nuclear factor-kappaB (RANK). Intriguingly, preincubation of mutant rRANKL5 with rRANKL1 before exposure to RANK enhanced the maximal binding level to RANK, indicating that rRANKL5 forms hybrid trimeric complexes with rRANKL1. Furthermore, RANKL mutant mimicking human RANKL V277 mutation in patients, impairs osteoclast differentiation and signaling. Taken together, these data lend support to the notion that the TNF-like core domain of RANKL contains structural determinants that are crucial for osteoclast differentiation and activation, thus providing a possible mechanistic explanation for the observed phenotype in osteopetrotic patients harboring RANKL mutations.

The regulation of RANKL by mechanical force

Role of OPG/RANKL/RANK system during alveolar bone resorption and remodeling

Mechanisms of RANKL delivery to the osteoclast precursor cell surface

Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation

Mechanisms involved in regulation of osteoclastic differentiation by mechanical stress-loaded osteoblasts

Mineralizing Solution and Dexamethasone Enhance Receptor Activator for NF-κB Ligand Expression in Rat Bone Marrow Stromal Cells

RANKL as the master regulator of osteoclast differentiation

RANKL biology: bone metabolism, the immune system, and beyond

The molecular understanding of osteoclast differentiation

TNF-family member Receptor Activator of NF-κB (RANK) and RANK-Ligand (RANKL) in bone remodelling

Osteoclast differentiation by RANKL and OPG signaling pathways

Tumor Necrosis Factor‐α Mediates RANK Ligand Stimulation of Osteoclast Differentiation by an Autocrine Mechanism †

Correlating Rank Ligand/Rank Binding Kinetics with Osteoclast Formation and Function

Receptor Activator of Nuclear Factor-Κb Ligand (rankl)/rank/osteoprotegerin System in Bone and Other Tissues (Review)

Receptor Activator Of Nuclear Factor-Kappa B Ligand (Rankl)/Rank/Osteoprotegerin System In Bone And Other Tissues

Signaling crosstalk between RANKL and interferons in osteoclast differentiation

Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases

Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

Functional Identification Of Three Receptor Activator Of Nf-Kappa B Cytoplasmic Motifs Mediating Osteoclast Differentiation And Function

Mutations within the TNF-Like Core Domain of RANKL Impair Osteoclast Differentiation and Activation